RODL (Red Okra–Diospyros) and Fecal Fat Excretion: A 2‑Day Randomized Trial
RODL وإخراج الدهون البرازي: تجربة عشوائية ليومين
Journal: Food & nutrition research
University: Not reported
Study Type: RCT
Evidence Level: preliminary
Participants: 70
Published:
⚠️ Warning: This is a preliminary study (animal/cell) and has not been proven in humans.
30-Second Summary
This is a randomized, double‑blind, placebo‑controlled clinical trial in 70 healthy adults testing a 2‑day RODL (red okra + Diospyros lotus) supplement versus placebo under a prescribed 130–150 g/day fat diet, with fecal fat measured before and after. The abstract describes the trial design and endpoints but does not report outcome values in the provided text.
1-Minute Summary
The paper reports a randomized, double‑blind, placebo‑controlled trial (N=70) assessing whether RODL (1.5 g/day) affects fecal fat excretion over a 2‑day intervention while participants consumed a controlled 130–150 g/day fat diet. Primary measurements were fecal fat content (mg/g wet and dry weight, and total mass) at baseline and post‑intervention. The trial design is appropriate for a short pharmacodynamic/biomarker readout, but the very short duration, modest sample size, and controlled diet limit generalizability to long‑term clinical outcomes. The abstract supplied does not include numerical results; interpretation should therefore be reserved until full results and statistical analyses are available in the full text.
3-Minute Summary
Background: Preclinical data indicate that a botanical combination of red okra (Abelmoschus esculentus) and Diospyros lotus (RODL™) may reduce intestinal fat absorption and modulate adipocyte lipid metabolism. Trial design: randomized, double‑blind, placebo‑controlled trial in 70 healthy adults (RODL n=34, placebo n=36) testing 1.5 g/day RODL versus placebo for 2 days while participants consumed a prescribed restricted diet (130–150 g/day fat). Primary outcome: change in fecal fat content measured as mg/g wet weight, mg/g dry weight, and total fecal fat mass; samples collected at baseline and after intervention. Key interpretation points: the abstract does not provide numerical outcome data, so efficacy and effect size cannot be assessed from the provided text. Strengths of the reported design include randomization, blinding, placebo control, and strict dietary control to reduce dietary confounding. Major limitations include the extremely short intervention period (2 days), unknown stool collection completeness and assay methods, lack of reported safety/adverse events, no power/sample‑size details in the abstract, and limited generalizability beyond healthy adults under a controlled diet. Clinical implications are therefore preliminary: an acute increase in fecal fat excretion would be mechanistically consistent with preclinical findings, but whether this translates to meaningful clinical effects (sustained fat loss, nutrient balance, or safety) requires full trial data and longer follow‑up studies.
Full Analysis
Context and rationale: Preclinical models reported dual actions for RODL™—intestinal fat binding/inhibition of absorption and effects on adipocyte lipid handling. A short clinical test of fecal fat excretion under a tightly controlled dietary fat intake directly addresses the first mechanism. Methodological appraisal: the trial is randomized, double‑blind and placebo‑controlled (N=70), which is an appropriate comparative design to limit bias. Diet standardization to 130–150 g/day fat reduces dietary confounding for fecal fat measurement. Primary endpoints (fecal fat mg/g wet and dry weight, and total mass) are objective and relevant to the hypothesized mechanism. Major limitations and unknowns: the intervention lasted only 2 days—suitable for detecting acute changes in fecal fat but not for assessing sustained metabolic or clinical outcomes. The abstract omits critical information: numerical outcomes, statistical significance, between‑group differences, methods for fecal fat quantification, compliance rates for stool collection, baseline balance of groups, randomization procedure, allocation concealment, handling of missing data, and safety/adverse event reporting. Sample size and power calculations are not reported in the abstract, leaving uncertainty about the trial’s ability to detect clinically meaningful differences. Interpretation and external validity: if RODL increased fecal fat excretion acutely, this would provide human evidence consistent with fat‑binding activity seen preclinically, but clinical relevance remains uncertain. Short‑term fecal fat increases can occur without producing long‑term weight loss or metabolic benefit; they could also affect absorption of fat‑soluble nutrients. Generalizability is limited: participants were healthy adults under a specified high‑fat controlled diet; effects in diverse populations, different diets, or with longer use are unknown. Next steps: obtain the full manuscript to review outcome magnitudes, statistical analyses, assay validation, adverse events, and follow‑up; conduct longer randomized trials with measures of nutrient status, body composition, and safety monitoring.Health Implications
Practical daily habits that may support healthy fat handling (without implying treatment): eat a balanced mix of whole foods—vegetables, fruit, whole grains, legumes, and lean proteins; include soluble fiber (oats, beans, vegetables) which may bind dietary fat and modulate absorption; limit highly processed and trans fats; distribute fat intake across meals rather than large single portions; stay physically active to support metabolism; ensure adequate hydration and regular meals to support digestion. Before starting supplements or botanical combinations, consult a healthcare professional—particularly if you take medications or have conditions affecting fat absorption or fat‑soluble vitamin status. These habits may support digestive and metabolic health but do not substitute for medical advice.
Key Findings
- Design and endpoint: a randomized, double‑blind, placebo‑controlled trial (N=70) testing 1.5 g/day RODL for 2 days with primary outcome fecal fat content (mg/g wet & dry weight, total mass).
- Interpretation caveats: the intervention is very short and performed under a prescribed diet; the abstract provided does not include outcome data, so clinical implications are preliminary and require the full results for assessment.